<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Marjin</title>
	<atom:link href="http://www.tapanray.in/tag/marjin/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Stakeholder Sentiment: Back to Square One?</title>
		<link>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-stakeholder-sentiment-back-to-square-one</link>
		<comments>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/#comments</comments>
		<pubDate>Mon, 28 May 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[guru]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[maximizing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[non-profit]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiment]]></category>
		<category><![CDATA[socializing]]></category>
		<category><![CDATA[square]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8965</guid>
		<description><![CDATA[Is it fair to push out the core purpose of an important process, or rather a mission, unfairly? Whether we like it or not, it happened that way, over a period of time. Way back on December 01, 1950, George W. &#8230; <a href="http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unsustainable New Cancer Drug Prices: Resolution Remains A Far Cry</title>
		<link>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry</link>
		<comments>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/#comments</comments>
		<pubDate>Mon, 13 Apr 2015 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Far Cry]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health-economics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[Mayo]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP 2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patented Drugs Pricing]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[public health foundation]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Sloan-Kettering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[unsustainable]]></category>
		<category><![CDATA[value based pricing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6530</guid>
		<description><![CDATA[Prices of new drugs for the treatment of life-threatening ailments, such as cancer, are increasingly becoming unsustainable, across the world, and more in India. As articulated by the American Society of Clinical Oncology in 2014, this is primarily due to &#8230; <a href="http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
